CY1112820T1 - Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βητα - Google Patents
Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βηταInfo
- Publication number
- CY1112820T1 CY1112820T1 CY20121100509T CY121100509T CY1112820T1 CY 1112820 T1 CY1112820 T1 CY 1112820T1 CY 20121100509 T CY20121100509 T CY 20121100509T CY 121100509 T CY121100509 T CY 121100509T CY 1112820 T1 CY1112820 T1 CY 1112820T1
- Authority
- CY
- Cyprus
- Prior art keywords
- interferonis
- reg
- beta
- pharmaceutical forms
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση σχετίζεται με μία υγρή φαρμακευτική σύνθεση η οποία περιλαμβάνει μία πεγκυλιωμένη ΙFΝ-β (ΡΕG-ΙFΝ-β), ένα έκδοχο, μία επιφανειοδραστική ουσία και ένα ρυθμιστικό διάλυμα όπου το εν λόγω έκδοχο είναι μία πολυόλη, όπου η εν λόγω επιφανειοδραστική ουσία είναι μία μη ιοντική επιφανειοδραστική ουσία και όπου το εν λόγω ρυθμιστικό διάλυμα είναι ένα ρυθμιστικό διάλυμα οξικού νατρίου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07150258 | 2007-12-20 | ||
US1025808P | 2008-01-07 | 2008-01-07 | |
EP08863833A EP2234645B1 (en) | 2007-12-20 | 2008-12-18 | Peg-interferon-beta formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112820T1 true CY1112820T1 (el) | 2016-02-10 |
Family
ID=39760852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100509T CY1112820T1 (el) | 2007-12-20 | 2012-06-06 | Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βητα |
Country Status (20)
Country | Link |
---|---|
US (1) | US9138403B2 (el) |
EP (1) | EP2234645B1 (el) |
JP (2) | JP5563475B2 (el) |
KR (1) | KR20100099298A (el) |
CN (1) | CN101878043A (el) |
AT (1) | ATE555812T1 (el) |
AU (1) | AU2008340058A1 (el) |
BR (1) | BRPI0821029A2 (el) |
CY (1) | CY1112820T1 (el) |
DK (1) | DK2234645T3 (el) |
EA (1) | EA201070773A1 (el) |
ES (1) | ES2387236T3 (el) |
HR (1) | HRP20120483T1 (el) |
IL (1) | IL206441A0 (el) |
PL (1) | PL2234645T3 (el) |
PT (1) | PT2234645E (el) |
RS (1) | RS52417B (el) |
SI (1) | SI2234645T1 (el) |
WO (1) | WO2009080699A2 (el) |
ZA (1) | ZA201001908B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201070773A1 (ru) * | 2007-12-20 | 2010-12-30 | Мерк Сероно С. А. | Составы пэг-интерферона-бета |
US20120269770A1 (en) * | 2010-11-22 | 2012-10-25 | Mark Brader | Stable Preserved Compositions of Interferon-Beta |
DK2968468T3 (en) * | 2013-03-13 | 2021-07-26 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
WO2016052584A1 (ja) * | 2014-09-30 | 2016-04-07 | 東レ株式会社 | ポリエチレングリコール修飾インターフェロン-βの検出及び定量に使用する試料液の前処理方法、ポリエチレングリコール修飾インターフェロン-βの検出方法及び定量方法 |
SG11201703646SA (en) * | 2014-11-10 | 2017-06-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Combination long acting compositions and methods for hepatitis c |
WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
KR101943160B1 (ko) * | 2016-10-06 | 2019-01-30 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
CN116023466B (zh) * | 2023-03-30 | 2023-06-27 | 北京生物制品研究所有限责任公司 | 纯化PEG修饰重组人干扰素β1b蛋白的方法 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4432895A (en) | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
US4469228A (en) | 1983-05-31 | 1984-09-04 | Schering Corporation | Interferon kit |
US4636383A (en) | 1984-08-29 | 1987-01-13 | Schering Corporation | Interferon-cyclaradine combination |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
IT1244511B (it) | 1991-04-15 | 1994-07-15 | Isi Ist Sierovaccinogeno Ital | Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione. |
KR950014915B1 (ko) | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | 탈시알로당단백-포함화합물 |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US5814485A (en) | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
ZA9610374B (en) | 1995-12-11 | 1997-06-23 | Elan Med Tech | Cartridge-based drug delivery device |
EP0949905B1 (en) | 1996-12-20 | 2001-07-18 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
SK284989B6 (sk) | 1996-12-24 | 2006-04-06 | Biogen, Inc. | Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu |
US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
WO1999015193A1 (de) | 1997-09-23 | 1999-04-01 | Rentschler Biotechnologie Gmbh & Co. Kg | FLÜSSIGE INTERFERON-β-FORMULIERUNGEN |
JP2001526033A (ja) | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | ヒトインターフェロン−イプシロンというi型インターフェロン |
KR100420642B1 (ko) | 1998-03-26 | 2004-03-02 | 쉐링 코포레이션 | Peg-인터페론 알파 결합체의 보호에 사용되는 제형 |
CZ298579B6 (cs) * | 1998-04-28 | 2007-11-14 | Applied Research Systems Ars Holding N. V. | Konjugát polyolu a interferonu-beta |
LT2599503T (lt) | 1998-10-16 | 2017-06-26 | Biogen Ma Inc. | Interferono beta-1a polimero konjugatai ir jų panaudojimas |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
CA2379388C (en) | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
CN1175901C (zh) | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6723606B2 (en) | 2000-06-29 | 2004-04-20 | California Institute Of Technology | Aerosol process for fabricating discontinuous floating gate microelectronic devices |
KR100396983B1 (ko) | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
PT1345593E (pt) | 2000-12-27 | 2007-10-10 | Ares Trading Sa | Micropartículas lipídicas por micronização criogénica |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
WO2003002152A2 (en) | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
NZ535008A (en) | 2002-02-08 | 2005-09-30 | Alkermes Inc | Polymer-based compositions for sustained release |
CN1235939C (zh) | 2002-05-14 | 2006-01-11 | 北京键凯科技有限公司 | 靶向亲水性聚合物、及其与干扰素的结合物以及包含该结合物的药物组合物 |
US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
EA009938B1 (ru) * | 2002-07-17 | 2008-04-28 | Байоджен Айдек Ма Инк. | ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β |
AU2003294757A1 (en) | 2002-11-29 | 2004-06-23 | Axxima Pharmaceuticals Ag | Formulations useful against hepatitis c virus infections |
EA008866B1 (ru) | 2002-12-26 | 2007-08-31 | Маунтин Вью Фамэсьютикэлс, Инк. | ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
EP1628686A2 (en) * | 2003-05-12 | 2006-03-01 | Affymax, Inc. | Spacer moiety for poly (ethylene glycol)-modified peptides |
AR044302A1 (es) | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
PT1666496E (pt) * | 2003-08-25 | 2014-06-24 | Toray Industries | Composto de interferão β |
PT1691825E (pt) | 2003-12-11 | 2011-10-12 | Ares Trading Sa | Formulações líquidas de interferão estabilizadas |
EP1734988A4 (en) * | 2004-03-01 | 2009-08-05 | Enzon Pharmaceuticals Inc | INTERFERON BETA-polymer |
KR20070012464A (ko) | 2004-05-17 | 2007-01-25 | 아레스 트레이딩 에스.아. | 하이드로겔 인터페론 제제 |
CN1993139B (zh) | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
CN1993138B (zh) | 2004-06-01 | 2010-12-15 | 阿雷斯贸易股份有限公司 | 稳定蛋白质的方法 |
CN101039660B (zh) * | 2004-08-12 | 2010-10-06 | 先灵公司 | 稳定的聚乙二醇化干扰素制剂 |
EA201070773A1 (ru) * | 2007-12-20 | 2010-12-30 | Мерк Сероно С. А. | Составы пэг-интерферона-бета |
-
2008
- 2008-12-18 EA EA201070773A patent/EA201070773A1/ru unknown
- 2008-12-18 BR BRPI0821029-2A patent/BRPI0821029A2/pt not_active IP Right Cessation
- 2008-12-18 DK DK08863833T patent/DK2234645T3/da active
- 2008-12-18 KR KR20107015882A patent/KR20100099298A/ko not_active Application Discontinuation
- 2008-12-18 ES ES08863833T patent/ES2387236T3/es active Active
- 2008-12-18 PL PL08863833T patent/PL2234645T3/pl unknown
- 2008-12-18 WO PCT/EP2008/067876 patent/WO2009080699A2/en active Application Filing
- 2008-12-18 SI SI200830666T patent/SI2234645T1/sl unknown
- 2008-12-18 RS RSP20120318 patent/RS52417B/en unknown
- 2008-12-18 JP JP2010538728A patent/JP5563475B2/ja not_active Expired - Fee Related
- 2008-12-18 CN CN2008801185845A patent/CN101878043A/zh active Pending
- 2008-12-18 AU AU2008340058A patent/AU2008340058A1/en not_active Abandoned
- 2008-12-18 PT PT08863833T patent/PT2234645E/pt unknown
- 2008-12-18 AT AT08863833T patent/ATE555812T1/de active
- 2008-12-18 EP EP08863833A patent/EP2234645B1/en active Active
- 2008-12-18 US US12/738,375 patent/US9138403B2/en not_active Expired - Fee Related
-
2010
- 2010-03-17 ZA ZA2010/01908A patent/ZA201001908B/en unknown
- 2010-06-17 IL IL206441A patent/IL206441A0/en unknown
-
2012
- 2012-06-06 CY CY20121100509T patent/CY1112820T1/el unknown
- 2012-06-08 HR HRP20120483AT patent/HRP20120483T1/hr unknown
-
2014
- 2014-04-07 JP JP2014078691A patent/JP2014159445A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI2234645T1 (sl) | 2012-07-31 |
IL206441A0 (en) | 2010-12-30 |
CN101878043A (zh) | 2010-11-03 |
ZA201001908B (en) | 2011-05-25 |
US9138403B2 (en) | 2015-09-22 |
BRPI0821029A2 (pt) | 2015-06-16 |
ATE555812T1 (de) | 2012-05-15 |
JP5563475B2 (ja) | 2014-07-30 |
WO2009080699A3 (en) | 2009-11-26 |
JP2014159445A (ja) | 2014-09-04 |
US20100239529A1 (en) | 2010-09-23 |
KR20100099298A (ko) | 2010-09-10 |
RS52417B (en) | 2013-02-28 |
EA201070773A1 (ru) | 2010-12-30 |
PL2234645T3 (pl) | 2012-10-31 |
AU2008340058A1 (en) | 2009-07-02 |
HRP20120483T1 (hr) | 2012-07-31 |
EP2234645B1 (en) | 2012-05-02 |
PT2234645E (pt) | 2012-05-21 |
ES2387236T3 (es) | 2012-09-18 |
EP2234645A2 (en) | 2010-10-06 |
JP2011506562A (ja) | 2011-03-03 |
WO2009080699A2 (en) | 2009-07-02 |
DK2234645T3 (da) | 2012-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112820T1 (el) | Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βητα | |
AR108998A2 (es) | Composición farmacéutica que contiene neurotoxina botulínica | |
RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
PE20090228A1 (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
CL2012000269A1 (es) | Formulacion farmaceutica inyectable subcutanea altamente concentrada de un anticuerpo anti-her2 que comprende dicho anticuerpo, un amortiguador, un estabilizador, un tensioactivo no ionico y una enzima hialuronidasa; dispositivo de inyeccion; kit y uso de la formulacion para tratar enfermedades tales como cancer. | |
ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
WO2007125103A3 (en) | Benzamide glucokinase activators | |
BR112013032396A2 (pt) | formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico | |
CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
ME01239B (me) | Čvrsti preparat koji sadrži alogliptin i pioglitazon | |
BRPI0923731A2 (pt) | "formulações injetáveis de toxinas botulínicas". | |
AU2009215514A9 (en) | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same | |
AR059978A1 (es) | Composiciones farmaceuticas | |
NZ600096A (en) | Formulations of antibody | |
HN2009000792A (es) | Inhibidores de la proteasa ns3 del hcv | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0807907A2 (pt) | co-cristais e composições farmacêuticas compreendendo os mesmos. | |
EA200970533A1 (ru) | Жидкие композиции антител против бешенства | |
WO2010147830A3 (en) | Aminothiazole modulators of beta-3-adrenoreceptor | |
FR2873585B1 (fr) | Nouvelles formulations galeniques de principes actifs | |
DK1899454T3 (da) | Serumfrit kulturmedium til fremstilling af rekombinante gonadotropiner | |
DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
DK2333056T3 (da) | Væskeformig sammensætning, der omfatter en asparaginprotease | |
NO20070187L (no) | Oralt desintegrerende farmasoytisk preparat omfattende risperidon |